key: cord-0021108-31i5i7tm
authors: Urakov, Aleksandr; Urakova, Natalya
title: Recent Insights into the Management of Inflammation in Asthma [Letter]
date: 2021-09-14
journal: J Inflamm Res
DOI: 10.2147/jir.s337690
sha: abdeb1c20b1e5f475b3b2d85e2a2ea31ded6c6d1
doc_id: 21108
cord_uid: 31i5i7tm

nan

patients. In our opinion, in this case, an additional search and analysis of information is a suitable method, for example, using the following keywords:

1. Expectorants 2. Mucolytics 3. Obstructive bronchitis 4. Respiratory obstruction 5. Solvent of mucus and sputum 6. Pus solvent 7. Biomechanics of respiration

The fact is that with additional studies and analysis of information, the possibility of using expectorants and mucolytics to reduce airway obstruction in patients with asthma will be shown. In addition, it may turn out that the use of these drugs will improve the effectiveness and safety of ICS. In addition, the possibility of using not only ICS, but also inhaled expectorants (IEP) for the successful treatment of asthma may be shown.

It is quite possible that with the help of such additional studies, it will be possible to optimize the treat-ment of asthma with ICS due to their combination with expectorants, mucolytics and/or drugs that dissolve pus in moderate and severe airway obstruction. For example, at the beginning of 2021 in Russia, the possibility of treating obstructive bronchitis with inhaled expectorants, including hydrogen peroxide and sodium bicarbonate, was shown. 2 Clarifying the potential possibilities of enhancing the therapeutic effect of ICS in asthma with the help of inhaled expectorants can expand the arsenal of antiasthmatic drugs and increase the effectiveness of asthma treatment in the future.

Recent insights into the management of inflammation in asthma

COVID-19: optimization of respiratory biomechanics by aerosol pus solvent

The authors report no conflicts of interest related to this communication.

Dove Medical Press encourages responsible, free and frank academic debate. The content of the Journal of Inflammation Research 'letters to the editor' section does not necessarily represent the views of Dove Medical Press, its officers, agents, employees, related entities or the Journal of Inflammation Research editors. While all reasonable steps have been taken to confirm the content of each letter, Dove Medical Press accepts no liability in respect of the content of any letter, nor is it responsible for the content and accuracy of any letter to the editor.

The Journal of Inflammation Research is an international, peerreviewed open-access journal that welcomes laboratory and clinical findings on the molecular basis, cell biology and pharmacology of inflammation including original research, reviews, symposium reports, hypothesis formation and commentaries on: acute/chronic inflammation; mediators of inflammation; cellular processes; molecular mechanisms; pharmacology and novel anti-inflammatory drugs; clinical conditions involving inflammation. The manuscript management system is completely online and includes a very quick and fair peerreview system. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.